1100 related articles for article (PubMed ID: 24076487)
1. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
2. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Dans AL; Connolly SJ; Wallentin L; Yang S; Nakamya J; Brueckmann M; Ezekowitz M; Oldgren J; Eikelboom JW; Reilly PA; Yusuf S
Circulation; 2013 Feb; 127(5):634-40. PubMed ID: 23271794
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
[TBL] [Abstract][Full Text] [Related]
4. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
5. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
7. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Paré G; Eriksson N; Lehr T; Connolly S; Eikelboom J; Ezekowitz MD; Axelsson T; Haertter S; Oldgren J; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Wadelius M; Zimdahl-Gelling H; Yusuf S; Wallentin L
Circulation; 2013 Apr; 127(13):1404-12. PubMed ID: 23467860
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
13. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
Stam-Slob MC; Connolly SJ; van der Graaf Y; van der Leeuw J; Dorresteijn JAN; Eikelboom JW; Peters RJG; Alings M; Visseren FLJ
Circulation; 2019 Jun; 139(25):2846-2856. PubMed ID: 31046423
[TBL] [Abstract][Full Text] [Related]
14. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Barrios V; Escobar C
Expert Opin Pharmacother; 2012 Dec; 13(18):2649-61. PubMed ID: 23167273
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
Hori M; Connolly SJ; Zhu J; Liu LS; Lau CP; Pais P; Xavier D; Kim SS; Omar R; Dans AL; Tan RS; Chen JH; Tanomsup S; Watanabe M; Koyanagi M; Ezekowitz MD; Reilly PA; Wallentin L; Yusuf S;
Stroke; 2013 Jul; 44(7):1891-6. PubMed ID: 23743976
[TBL] [Abstract][Full Text] [Related]
17. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
18. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
19. Effects of dabigatran according to age in atrial fibrillation.
Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
[TBL] [Abstract][Full Text] [Related]
20. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Clemens A; Haertter S; Friedman J; Brueckmann M; Stangier J; van Ryn J; Lehr T
Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
